NRx Pharmaceuticals’ (NRXP) “Buy” Rating Reaffirmed at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of NRx Pharmaceuticals (NASDAQ:NRXP) in a research report report published on Monday,Benzinga reports. D. Boral Capital currently has a $34.00 price objective on the stock.

NRXP has been the subject of several other reports. Ascendiant Capital Markets reiterated a “buy” rating and set a $48.00 price objective (up from $47.00) on shares of NRx Pharmaceuticals in a report on Friday, January 2nd. BTIG Research reiterated a “buy” rating and set a $25.00 price objective on shares of NRx Pharmaceuticals in a report on Tuesday, March 24th. HC Wainwright increased their price objective on NRx Pharmaceuticals from $40.00 to $45.00 and gave the stock a “buy” rating in a report on Tuesday, March 3rd. Zacks Research upgraded NRx Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, March 2nd. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of NRx Pharmaceuticals in a report on Monday, December 29th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $38.00.

NRx Pharmaceuticals Stock Up 25.5%

Shares of NRx Pharmaceuticals stock opened at $3.20 on Monday. The stock has a market cap of $105.82 million, a PE ratio of -2.30 and a beta of 1.83. The business has a fifty day simple moving average of $2.03 and a 200-day simple moving average of $2.35. NRx Pharmaceuticals has a 12 month low of $1.62 and a 12 month high of $3.84.

NRx Pharmaceuticals (NASDAQ:NRXP) last issued its earnings results on Monday, March 23rd. The company reported $0.19 EPS for the quarter, topping the consensus estimate of ($0.09) by $0.28. The business had revenue of $0.98 million during the quarter, compared to analyst estimates of $7.53 million. Analysts expect that NRx Pharmaceuticals will post 0.13 EPS for the current fiscal year.

Institutional Trading of NRx Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the company. Anson Funds Management LP raised its holdings in NRx Pharmaceuticals by 50.3% during the fourth quarter. Anson Funds Management LP now owns 3,043,957 shares of the company’s stock valued at $8,249,000 after buying an additional 1,018,853 shares in the last quarter. Vanguard Group Inc. raised its holdings in NRx Pharmaceuticals by 18.3% during the third quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock valued at $1,765,000 after buying an additional 82,781 shares in the last quarter. Commonwealth Equity Services LLC bought a new position in NRx Pharmaceuticals during the fourth quarter valued at about $994,000. AdvisorShares Investments LLC raised its holdings in NRx Pharmaceuticals by 29.7% during the third quarter. AdvisorShares Investments LLC now owns 342,136 shares of the company’s stock valued at $1,129,000 after buying an additional 78,339 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in NRx Pharmaceuticals by 17.8% during the fourth quarter. Geode Capital Management LLC now owns 218,866 shares of the company’s stock valued at $593,000 after buying an additional 33,004 shares in the last quarter. 4.27% of the stock is currently owned by hedge funds and other institutional investors.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.